MOLECULAR-GENETIC PREDICTORS OF CIRRHOSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C
Keywords:
chronic hepatitis c (CHC), cirrhosis, molecular-genetic predictors, fibrosis progression , genetic polymorphisms, pro-inflammatory cytokines, personalized medicineAbstract
The modern era of hepatology has witnessed extraordinary progress in treating and controlling CHC through DAAs, which have significantly improved cure rates. However, several current realities and challenges emphasize the importance (актуалности) of investigating molecular-genetic predictors of disease progression: Residual Burden of Cirrhosis and HCC: Even with effective antiviral therapies, many patients already have significant fibrotic changes by the time of diagnosis. Understanding who is at the highest risk of advanced disease remains crucial. Resource Allocation: In settings with limited healthcare resources, prioritizing patients at the greatest risk of cirrhosis progression can help direct therapeutic and monitoring resources efficiently. Personalized Medicine: As precision medicine advances, genetic markers provide a potential roadmap to tailor treatment durations, intensities, and follow-up intervals. This aligns with the global trend toward individualized healthcare. Persistent Inflammatory Drive: Certain genetic variants in IL28B, PNPLA3, and cytokine-related genes may continue to drive low-grade inflammation and fibrogenesis, even after viral eradication. This highlights the need for long-term surveillance and possible adjunctive anti-fibrotic treatments. Future Therapeutic Targets: Knowledge of molecular-genetic pathways involved in CHC progression can spur the development of novel therapeutic agents aimed at halting or reversing fibrosis.
Hence, the topical relevance (актуалности) of studying genetic predictors in CHC lies in addressing the ongoing global burden of cirrhosis and HCC, optimizing healthcare resource use, and paving the way for more tailored, precise medical interventions.
References
World Health Organization. Global Hepatitis Report. Geneva: WHO; 2017.
Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19(7):850–858.
Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–176.
Stättermayer AF, Strassl R, Maieron A, et al. Genetic factors in hepatitis C: Impact on disease susceptibility and treatment response. Clin Sci (Lond). 2015;129(6):431–447.
Абдукодиров, Ш. Т. "ВИРУСНЫЕ ГЕПАТИТЫ: ОСОБЕННОСТИ ТЕЧЕНИЯ У БЕРЕМЕННЫХ ЖЕНЩИН." In Russian-Uzbekistan Conference, vol. 1, no. 1. 2024..
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
Юлдашев, Я. М. "ЭФЕКТИВНОСТЬ ЛЕЧЕНИЯ ЛИМОННЫМ СОКОМ ПРИ ВИРУСНОМ ГЕПАТИТЕ В ПРОТЕКАЮЩЕГО С ХОЛЕСТАТИЧЕСКИМ КОМПОНЕНТОМ МЕТОДОМ «ДЮБАЖ»." In Russian-Uzbekistan Conference, vol. 1, no. 1. 2024.
Mirzakarimova, D. B., G. M. Hodjimatova, and Sh T. Abdukodirov. "FEATURES OF PATHOGENESIS, CLINICAL PICTURE AND DIAGNOSIS OF CO-INFECTION OF THE LIVER WITH HEPATITIS B AND C VIRUSES." International Multidisciplinary Journal for Research & Development 11, no. 02 (2024).
Trepo E, Valenti L. Update on PNPLA3 and alcoholic liver disease. Biomedicines. 2020;8(11):223.
Gulamovich, Djurayev Muzaffar. "Classification of the most common infectious diseases today." International Multidisciplinary Journal for Research & Development 10, no. 10 (2023).
Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
